This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of ~~Compounds of the~~ formula I



I

in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes H, A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^2 if X = N

is absent or

if X = C

denotes H, A, Hal, CN, $-(CH_2)_p$-Ar,

$-(CH_2)_p$-COOH, $-(CH_2)_p$-COOA, $-(CH_2)_p$-Het^3,

$-(CH_2)_p$-NH_2, SO_2A, CHO or COA,

R^3 denotes H, A, -S-A, $-(CH_2)_p$-Ar, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Ar, NH-$(CH_2)_p$-Het, NH_2, NHA, NA_2, NH-alkylene-NH_2, NH-alkylene-NHA, NH-alkylene-NA_2 or NA-alkylene-NA_2,

R^4 denotes $-(CH_2)_s$-$(Ar^I)_n$-Y-R^6,

R^5 denotes H or CH_3, or

R^4 and R^5 together ~~also~~ denote Het^4—N(-CH_2-CH_2-)(-CH_2-CH_2-),

R^6 denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2$-COOH or $-OCH_2$-COOH,

Ar^1 denotes phenylene or piperazinediyl,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, OA, COOA, CN, $-(CH_2)_p$-Ar, $-(CH_2)_t$-OH, $-(CH_2)_p$-Het^1 or carbonyl oxygen (=O),

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Het^2 denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^3 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

m denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4-$ or

R^2 and R^3 together may also denote $-(CHR^7-CHR^8-NR^9-CHR^{10})-$,

and, if Ar^1 denotes piperazinediyl,

R^6 may also denote H or alkyl having 1-6 C atoms,

or a pharmaceutically acceptable solvate, tautomer, salt or stereoisomer thereof ~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

2. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
m	denotes 0,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,
s	denotes 0 or 1,
n	denotes 1,
Ar^1	denotes phenylene,
R^6	denotes Het^4,
Y	denotes O,
Het^4	denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 1,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 1, 2, 3 or 4,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,

Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

7. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 1, 2, 3 or 4,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-or disubstituted by A;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m-Ar$,	
m	denotes 0,	
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,	
R^2	if X = N	is absent or
	if X = C	denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p-Het$;	

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	if X = N is absent or
	if X = C denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
r	denotes 1, 2, 3 or 4;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
r	denotes 0;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

11. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in

which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

12. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

13. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m-Ar$,	
m	denotes 0,	
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,	
R^2	if X = N	is absent or
	if X = C	denotes CN,

R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,

~~and pharmaceutically-usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

14. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar,	
m	denotes 0,	
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,	
R^2	if X = N	is absent or
	if X = C	denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,	
R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,	
s	denotes 0,	
n	denotes 1,	
Ar^1	denotes phenylene,	
R^6	denotes Het^4,	
Y	denotes O,	
Het^4	denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl,	

~~and pharmaceutically-usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

15. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O or $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
Ar^1	denotes phenylene~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

16. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t-OH$ or $-(CH_2)_p-Het^1$,
Het^1	denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms,

or ~~[[f]]~~  [[~~,~~]]

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and~~

~~stereoisomers thereof, including mixtures thereof in all ratios~~.

17. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl

or [[~~I~~]]



[[~~I~~]]

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

18. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O, $(CH_2)_q$ or NH,
Ar^1	denotes phenylene,
q	denotes 0, 1, 2, 3 or 4,
R^6	denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,
r	denotes 0, 1, 2, 3 or 4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A or ~~and/or~~ Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and~~

~~stereoisomers thereof, including mixtures thereof in all ratios~~.

19. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	if X = N is absent or if X = C denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,
Het^1	denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or [[~~f~~]]



[[~~,~~]]

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

20. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
s	denotes 0, 1, 2, 3 or 4,
n	denotes 0 or 1,
Y	denotes O or $(CH_2)_q$,

Ar^1	denotes phenylene,
q	denotes 0,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4,
Het^4	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

21. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A or ~~and/or~~ Ar^2,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

22. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^4	denotes 4-(pyridin-4-yloxy)phenyl, 4-(pyridin-4-yloxy)-phenylmethyl or 4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl, where the pyridine radical may be substituted by $CONHCH_3$,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

23. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het^1	denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or [[f]]  [[7]]

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

24. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het^1 denotes morpholinyl, pyrrolidinyl, piperidinyl, pyridyl

or [[f]]  [[7]]

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

25. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

Het^2 denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

26. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

R^2 if X = N

is absent or

if X = C

denotes H, CN, COOA or phenyl,

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, $NH-(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

27. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^2 if X = N

is absent or

if X = C

denotes H, CN, $(CH_2)_oAr''$, $(CH_2)_oCOOA$ or SO_2A,

Ar'' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o denotes 0 or 1;

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

28. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

29. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

X denotes C or N,

B	denotes N, CH or C-CN,
R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,
Ar'	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,
m	denotes 0,
Het^2	denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,
R^2	if X = N is absent or if X = C denotes H, CN, $(CH_2)_o$Ar'', $(CH_2)_o$COOA or SO_2A,
Ar''	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,
o	denotes 0 or 1,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl
	or [[~~f~~]]  [[~~r~~]]
R^4	denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3, or
R^4 and R^5	together ~~also~~ denote  ,
R^6	denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine,

thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,

Ar^1 denotes phenylene or piperazinediyl,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4$- or

R^2 and R^3 together may also denote $-(CHR^7\text{-}NR^8\text{-}CHR^9\text{-}CHR^{10})$-,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

30. (Currently Amended) <u>A compound</u> ~~Compounds~~ according to Claim 1 in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2	denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms,
R^2	if X = N is absent or if X = C denotes H, CN, $(CH_2)_oAr''$, $(CH_2)_oCOOA$ or SO_2A,
Ar''	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,
o	denotes 0 or 1,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl or [[ŧ]]  [[ŧ]]
R^4	denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3, or
R^4 and R^5	together ~~also~~ denote  ,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
Het^4	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,

Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
R^7, R^8, R^9, R^{10}	each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4$- or

R^2 and R^3 together may also denote $-(CHR^7-NR^8-CHR^9-CHR^{10})-$,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

31. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

X	denotes N,
B	denotes N, CH or C-CN,
R^1	denotes NH_2,
R^2	is absent,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, $NH-(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di-

	or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl
	or [[~~t~~]]  [[,]]
R^4	denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3, or
R^4 and R^5	together ~~also~~ denote  ,
R^6	denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and~~

~~stereoisomers thereof, including mixtures thereof in all ratios~~.

32. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 in which

X	denotes N,
B	denotes N, CH or C-CN,
R^1	denotes NH_2,
R^2	is absent,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, $NH-(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl
	or [[~~f~~]]  [[~~7~~]]
R^4	denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3, or
R^4 and R^5	together ~~also~~ denote  ,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
Het^4	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,

Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms~~,~~

~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

33. (Currently Amended) A compound, which is ~~Compounds according to Claim 1, selected from the group~~

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,





(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,

(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,

7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,

5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,







,





,



,



,



,

6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,



,



,



,



,



,



,



,



,



,



,



,































,



,



,



,



,



,



,
















,


,


,


,


,


,


,


Cl
N
H
N
N
N
O
N
N
S
,


Cl
N
H
N
N
N
N
S
N
,


Cl
N
H
N
N
N
N
S
N
N
,


Cl
N
H
N
N
N
N
S
N
N
,


Cl
N
N
H
N
N
S
N
N
,


,


,


,


,


,


,


,


,


,


,













,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,


,


,


,


,



,



,



,



,



,



,















,



,



,



,



,



,



,



,



,



,













,



,



,



,



,



,



,



,



,



,



,



,



,



, or



or a pharmaceutically acceptable solvate, tautomer, salt or stereoisomer thereof ~~and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

34. (Currently Amended) A process for preparing a compound ~~Process for the preparation of compounds of the formula I~~ according to Claim 1 or a pharmaceutically acceptable solvate, tautomer, salt or stereoisomer thereof, comprising ~~and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that~~

a) for the preparation of compounds of the formula I

in which X denotes C,

reacting a compound of ~~the~~ formula II



II

,

in which R^4, R^5 and B have the meanings indicated for the compound of formula I ~~in Claim 1~~,

i) ~~is reacted~~ with a compound of ~~the~~ formula IIIa



IIIa

,

in which R^1 OA and R^2 and R^3 have the meanings indicated for the compound of formula I ~~in Claim 1~~,

or

ii) with a compound of ~~the~~ formula IIIb



IIIb

,

in which R^1, R^2 and R^3 have the meanings indicated for the compound of formula I ~~in Claim 1~~,
and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

iii) with a compound of ~~the~~ formula IIIc



IIIc

,

in which

R^1, besides the meanings indicated for the compound of formula I ~~in Claim 1~~, also denotes OA,

R^2 and R^3 have the meanings indicated for the compound of formula I ~~in Claim 1~~,

and A, A' each, independently of one another, denote alkyl having 1, 2, 3 or 4 C atoms,

or A and A' together ~~may also~~ form a butylene or pentylene chain,

or

b) for the preparation of compounds of the formula I

in which X denotes N and R^1 denotes NH_2,

reacting a compound of ~~the~~ formula II ~~is reacted~~ with a compound of ~~the~~ formula IIId



IIId

in which R^3 has the meaning indicated for the compound of formula I ~~in Claim 1~~,

and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

c) for the preparation of compounds of the formula I in which

X denotes N,

R^1 denotes H, A, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^3 denotes -S-A

reacting a compound of ~~the~~ formula II ~~is reacted~~ with a compound of ~~the~~ formula IIIe



IIIe

in which

R^1 denotes H, A, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2

and A denotes alkyl having 1, 2, 3 or 4 C atoms,

and/or ~~that~~ one or more radical(s) R^1,R^2 and/or R^3 in a compound of ~~the~~ formula I is (are) converted into one or more other radical(s) R^1,R^2 and/or R^3,

~~by, for example,~~

~~i) converting an alkylsulfanyl group into an amine,~~

~~ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol,~~

~~iii) reducing a nitrile to the aldehyde or amine,~~

and/or

a base or acid of a compound of ~~the~~ formula I is converted into one of its salts.

35. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier ~~Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and~~

~~stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants~~.

36-57. (Cancelled)

58. (New) A process according to claim 34, wherein one or more radical(s) R^1,R^2 and/or R^3 in a compound of formula I is (are) converted into one or more other radical(s) R^1,R^2 and/or R^3, by

i) converting an alkylsulfanyl group into an amine,

ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol, or

iii) reducing a nitrile to the aldehyde or amine.

59. (New) A pharmaceutical composition comprising a compound according to claim 33 and a pharmaceutically acceptable carrier.

60. (New) A compound of formula I according to claim 1,
in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes H, A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^2 if X = N
is absent or
if X = C
denotes H, A, Hal, CN, $-(CH_2)_p$-Ar,
$-(CH_2)_p$-COOH, $-(CH_2)_p$-COOA, $-(CH_2)_p$-Het^3,
$-(CH_2)_p$-NH_2, SO_2A, CHO or COA,

R^3 denotes H, A, -S-A, $-(CH_2)_p$-Ar, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Ar, NH-$(CH_2)_p$-Het, NH_2, NHA, NA_2, NH-alkylene-NH_2, NH-alkylene-NHA, NH-alkylene-NA_2 or NA-alkylene-NA_2,

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

R^5 denotes H or CH_3, or

R^4 and R^5 together denote $Het^4-N<^{CH_2-CH_2-}_{CH_2-CH_2-}$,

R^6 denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2-COOH$ or $-OCH_2-COOH$,

Ar^1 denotes phenylene or piperazinediyl,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, OA, COOA, CN, $-(CH_2)_p-Ar$, $-(CH_2)_t-OH$, $-(CH_2)_p-Het^1$ or carbonyl oxygen (=O),

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Het^2 denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^3 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

m denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4$- or

R^2 and R^3 together may also denote $-(CHR^7-CHR^8-NR^9-CHR^{10})$-,

and, if Ar^1 denotes piperazinediyl,

R^6 may also denote H or alkyl having 1-6 C atoms,

or a pharmaceutically acceptable salt thereof.

61. (New) A pharmaceutical composition comprising a compound according to claim 60 and a pharmaceutically acceptable carrier.

62. (New) A compound according to claim 33, which is

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,





(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,

(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,

7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,

5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,





,



,





,



,



,



6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,





,



,



,



,



,



,



,



,



,



,



,



,



















,



,



,



,



,



,



,

















,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,


,


,


,


,


,


,















































,



,



,



,



,



,



































,



,



,



,



, or



or a pharmaceutically acceptable salt thereof.

63. (New) A pharmaceutical composition comprising a compound according to claim 61 and a pharmaceutically acceptable carrier.

64. (New) A compound according to claim 1 in which X denotes C.

65. (New) A compound according to claim 1 in which X denotes N.

66. (New) A compound according to claim 60 in which X denotes C.

67. (New) A compound according to claim 60 in which X denotes N.

68. (New) A pharmaceutical composition comprising a compound according to claim 66 and a pharmaceutically acceptable carrier.

69. (New) A pharmaceutical composition comprising a compound according to claim 67 and a pharmaceutically acceptable carrier.